AMENDMENTS TO THE CLAIMS:

Please AMEND the claims as follows:

- 1. (Currently Amended) An implantable bio-ablation composition comprising a first coding sequence that encodes and expresses, in atrioventricular node cells, a molecule that decreases expression of L-type Ca²⁺ channels and thereby suppresses cellular excitability and a second coding sequence that encodes and expresses a protein that decreases the conductance of an ion-channel L-type Ca²⁺ channels responsible for cellular excitability, wherein expression of both the first and second sequences is effective to substantially extinguish conduction through the atrioventricular node.
- (Currently Amended) The bio-ablation composition of claim 1, wherein the
 molecule that <u>decreases expression of L-type Ca²⁺ channels and thereby</u>
 suppresses cellular excitability is a regulatory G-protein.
- (Original) The bio-ablation composition of claim 2, wherein the G-protein is kir/GEM.
- (Canceled).
- (Canceled).
- 6. (Original) The bio-ablation composition of claim 1, wherein the protein that decreases ion channel conductance is G_i.
- (Canceled).
- 8. 45. (Canceled).

Appl. No. 10/626,159 Reply to Office Action of September 12, 2006 Page 4

- 46. (New) The bio-ablation composition of claim 1, wherein the composition comprises a viral vector that includes the first and second coding sequences.
- 47. (New) The bio-ablation composition of claim 46, wherein the viral vector is a vector selected from the group consisting of a retroviral vector, an adenoviral associated vector, a vaccinia virus vector, and a Semliki Foret virus vector.
- 48. (New) The bio-ablation composition of claim 47, wherein the viral vector is an adenoviral associated vector.
- 49. (New) The bio-ablation composition of claim 6, wherein the composition comprises a sufficient amount of the G_i to overexpress G_i in the atrioventricular node.
- 50. (New) The bio-ablation composition of claim 2, wherein the composition comprises a sufficient amount of kir/GEM to overexpress kir/GEM in the atrioventricular node.
- 51. (New) An implantable bio-ablation composition comprising a first coding sequence that encodes and expresses kir/GEM in atrioventricular node cells and a second coding sequence that encodes and expresses G_i in atrioventricular node cells, wherein expression of the sequences is effective to substantially extinguish conduction through the atrioventricular node.
- (New) The bio-ablation composition of claim 51, wherein the composition comprises a viral vector that includes the first and second coding sequences.
- 53. (New) The bio-ablation composition of claim 52, wherein the viral vector is a vector selected from the group consisting of a retroviral vector, an adenoviral associated vector, a vaccinia virus vector, and a Semliki Foret virus vector.

Appl. No. 10/626,159 Reply to Office Action of September 12, 2006

- 54. (New) The bio-ablation composition of claim 53, wherein the viral vector is an adenoviral associated vector.
- 55. (New) The bio-ablation composition of claim 51, wherein the composition comprises a sufficient amount of the G_i to overexpress G_i in the atrioventricular node.
- 56. (New) The bio-ablation composition of claim 51, wherein the composition comprises a sufficient amount of kir/GEM to overexpress kir/GEM in the atrioventricular node.